

# Exhibit 2

Premarket Approval (PMA)

 U.S. Department of Health & Human Services a A A

 **U.S. Food and Drug Administration**  
Protecting and Promoting Your Health

A to Z Index | Follow FDA | En Español SEARCH

Most Popular Searches

Home | Food | Drugs | Medical Devices | Radiation-Emitting Products | Vaccines, Blood & Biologics | Animal & Veterinary | Cosmetics | Tobacco Products

## Premarket Approval (PMA)

 [CDRH SuperSearch](#)

[510\(k\)](#) | [DeNovo](#) | [Registration & Listing](#) | [Adverse Events](#) | [Recalls](#) | [PMA](#) | [HDE](#) | [Classification](#) | [Standards](#)  
[CFR Title 21](#) | [Radiation-Emitting Products](#) | [X-Ray Assembler](#) | [Medsun Reports](#) | [CLIA](#) | [TPLC](#) | [Inspections](#)

[New Search](#) [Back to Search Results](#)

Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the [original PMA](#) to get an up-to-date view of this device.

<b>Trade Name</b>	JUVEDERM ULTRA XC AND JUVEDERM ULTRA PLUS XC
<b>Classification Name</b>	<a href="#">Implant, Dermal, For Aesthetic Use</a>
<b>Generic Name</b>	Juvederm Gel Implants
<b>Applicant</b>	ALLERGAN
<b>PMA Number</b>	P050047
<b>Supplement Number</b>	S005
<b>Date Received</b>	08/18/2008
<b>Decision Date</b>	01/07/2010
<b>Product Code</b>	LMH <a href="#">[ Registered Establishments With LMH ]</a>
<b>Advisory Committee</b>	General & Plastic Surgery
<b>Clinical Trials</b>	<a href="#">NCT00653861</a>
<b>Supplement Type</b>	Normal 180 Day Track
<b>Supplement Reason</b>	Change Design/Components/Specifications - Component
<b>Expedited Review Granted?</b>	No
<b>Combination Product</b>	<a href="#">Yes</a>
<b>Review Memo</b>	
<a href="#">Review Memo</a>	
<b>Approval Order Statement</b>	
Approval for the addition of 0.3% lidocaine into juvederm ultra and juvederm ultra plus. The device, as modified, will be marketed under the trade name juvederm ultra xc and juvederm ultra plus xc and is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).	
<b>Approval Order</b>	
<a href="#">Approval Order</a>	

Page Last Updated: 03/23/2015

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

 [Accessibility](#) | [Contact FDA](#) | [Careers](#) | [FDA Basics](#) | [FOIA](#) | [No Fear Act](#) | [Site Map](#) | [Transparency](#) | [Website Policies](#)

**U.S. Food and Drug Administration**  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Combination Products  
Advisory Committees

 U.S. Department of Health & Human Services

Premarket Approval (PMA)

Ph. 1-888-INFO-FDA (1-888-463-6332)

Email FDA



For Government | For Press

Science & Research

Regulatory Information

Safety

Emergency Preparedness

International Programs

News & Events

Training and Continuing Education

Inspections/Compliance

State & Local Officials

Consumers

Industry

Health Professionals

FDA Archive